ASTRO/SNMMI Joint Session: Unlocking Success in Radiopharmaceutical Therapy: Collaboration between Radiation Oncology, Nuclear Medicine and Industry
Theranostics, a treatment paradigm pairing diagnostic molecular imaging with radiopharmaceutical therapy (RPT), is resurgent, mainly driven by the FDA approvals of 177Lu-dotatate for neuroendocrine tumors and 177Lu-PSMA-617 for prostate cancer.
Category
  • Radiopharmaceutical Therapy
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Precision in Practice: The Critical Role of Radiation Dosimetry in Radiotherapeutic Pharmaceuticals
Radiation dosimetry plays a critical role in the development and application of radiotherapeutic pharmaceuticals, ensuring both efficacy and safety in treatment.
Category
  • Radiopharmaceutical Therapy
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Leveraging Anti-Tumor Immunity with Radiopharmaceutical Therapy (RPT) and Potential Combinatorial Approaches with RPT and Immunotherapy
Radiopharmaceutical Therapy (RPT) is an emerging modality with significant potential to impact future oncological management across many disease settings.
Category
  • Radiopharmaceutical Therapy
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Advanced Treatment Techniques of Stereotactic, Adaptive and Protons for Gynecologic Cancer – Tips, Tricks and Patient Selection
This activity discusses some of the newer treatment techniques, including stereotactic body radiation (SBRT), adaptive radiation therapy and protons being utilized in gynecologic cancer.
Category
  • Adaptive RT
  • Gynecologic
  • Oligometastatic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Oligometastatic Prostate Cancer: A Multidisciplinary Approach to Patient Care
This activity is a case-based discussion with a panel of experts in the field of GU malignancies discussing how to personalize treatment recommendations based on imaging (including MRI, Fluciclovine F18 and Ga68-PSMA scans), pathology and clinical findings for patients with oligometastatic diseas
Category
  • Genitourinary
  • Oligometastatic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Multidisciplinary Management of Lung Cancer in the Patient with Interstitial Lung Disease
Patients with interstitial lung disease (ILD), especially those with pulmonary fibrosis, are at increased risk of developing lung cancer. Management of lung cancer in patients with ILD is particularly challenging.
Category
  • Thoracic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Radiopharmaceutical Therapy Workshop 2024
Radiopharmaceuticals are an increasingly utilized therapeutic option for the treatment of malignancies.
Category
  • Radiopharmaceutical Therapy
Format
  • Sessions onDemand
Credits
  • 4.50 AMA PRA Category 1 Credit™
  • 4.50 Certificate of Attendance
Cost $379.00
Optimizing Sequencing in Immunotherapy and Radiotherapy for Non-Small Cell Lung Cancer – Clinical and Translational Advances
This combined immunotherapy track and lung cancer track brings together leading experts to discuss recent, cutting-edge trials and strategies in treating both locally advanced and metastatic non-small cell lung cancer (NSCLC). Dr.
Category
  • Immunotherapy
  • Thoracic
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Multidisciplinary Lung Cancer Tumor Board: A Case-Based Discussion Spanning Bread-and-Butter through the Gray Zone
The management of locally advanced lung cancer increasingly relies on multidisciplinary collaboration. Advances in neoadjuvant and perioperative chemoimmunotherapy have significantly improved outcomes for patients with resectable non-small cell lung cancer.
Category
  • Thoracic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Designing, Implementing and Interpreting Patient Reported Outcomes in Clinical Investigation
Patient reported outcomes (PROs) are a key component of evaluating cancer therapy. For clinical trialists, the proper design, implementation and evaluation of patient reported outcomes is critical for designing studies that will impact and inform daily practice.
Category
  • Professional Development
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00

Pages